CSL (ASX:CSL) share price trades flat despite annual R&D update

Here's what CSL is working on…

| More on:
woman in lab coat conducting testing representing biotech

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price is trading broadly flat on Tuesday morning following the release of its annual research and development (R&D) update.

At the time of writing, the biotherapeutics company's shares are fetching $294.15.

CSL share price flat following R&D update

During FY 2021, CSL invested more than US$1 billion in its R&D activities across six therapeutic areas, four scientific platforms, and two businesses.

Management notes that there were a number of highlights during the period. These include:

The Seqirus business advancing its first-of-its-kind adjuvanted, cell-based seasonal influenza vaccine (aQIVc) and increasing its work on its self-amplifying mRNA (sa-mRNA) development program. In fact, earlier this month, the Biomedical Advanced Research and Development Authority (BARDA) awarded Seqirus a multi-year contract to provide clinical development services to evaluate the safety, immunogenicity, and dose-sparing capability of two H2Nx influenza vaccine candidates. One is using a combination of Seqirus' FDA-licensed cell-based and adjuvanted technologies, and the other is using its next generation sa-mRNA platform.

CSL has started a new collaboration with the Walter and Eliza Hall Institute for Medical Research (WEHI). This is one of the most prominent medical research and medicine development organisations in Australia. The two parties will work together to create a Centre for Biologic Therapies.

Another item highlighted by management is the impending Phase III study of 4-Factor Prothrombin Complex Concentrate to improve survival rates in traumatic injury and acute major bleeding. In addition, the company notes that the VANGUARD Phase III clinical trial for Garadacimab, a treatment in hereditary angioedema (HAE), has enrolled its last patient two months ahead of schedule. Recruitment from the AEGIS-II Phase III study of CSL112 (ApoA-1) for treatment of acute coronary syndrome is also progressing despite COVID-19 impact on clinical trial sites and patients.

Finally, on the licence front, CSL revealed that preparations are underway for EtranaDez, a gene therapy for haemophilia B, to submit a Biologics Licence Application for the US and Marketing Authorisation Application for the EU.

Management commentary

CSL's Executive Vice President, Head of R&D, and Chief Medical Officer, Dr. Bill Mezzanotte, commented: "We continue to evolve as a leading plasma-based biotechnology company with purposeful diversity in therapeutic areas, scientific platforms and strategic alliances."

"We are continuing to invest in our core plasma business while also enhancing our other scientific platforms to better deliver on our promise to discover, develop and provide innovations that save and improve lives around the world," he added.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Man with rocket wings which have flames coming out of them.
Share Gainers

Up 99% in a year, guess which ASX 300 stock is rocketing higher again today

Investor are piling into the $1.6 billion ASX 300 company again today. But why?

Read more »

Two brokers analysing stocks.
Energy Shares

Santos shares push higher on takeover update

What is the latest on this potential deal? Let's find out.

Read more »

A female soldier flies a drone using hand-held controls.
Share Market News

DroneShield shares charge higher on more big news

This high-flying stock has announced another important contract win.

Read more »

A business woman looks unhappy while she flies a red flag at her laptop.
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

a man in a business suit sits at his laptop computer at his desk and smiles broadly in an office setting, giving an air of optimism and confidence.
Opinions

This ASX 200 share has made the most money for my portfolio. I'm expecting a lot more

There’s one key reason why I’m expecting strong growth from this stock.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
Share Market News

These ASX 200 stocks doubled in FY25. Can they do it again in FY26?

Let's find out.

Read more »

Woman on her phone with diagrams of tech sector related elements linking with each other.
Share Market News

Which magnificent 7 stock would I buy today with $5,000?

One stands above the rest.

Read more »

A man in trendy clothing sits on a bench in a shopping mall looking at his phone with interest and a surprised look on his face.
Share Market News

5 things to watch on the ASX 200 on Monday

It looks set to be a decent start to the week for Aussie investors.

Read more »